Compass Pathways Plc

Compass Pathways plc is a biotechnology company focused on mental health, operating in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for treatment-resistant depression and in Phase II clinical trials for post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. Incorporated in 2020, it is headquartered in London, United Kingdom.